今日观察！A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.

上海雅仕慷慨回馈股东 每股派发0.1元现金红利 股权登记日为6月20日

上海，2024年6月18日 - 上海雅仕投资发展股份有限公司（证券代码：603329.SH）今日发布公告，宣布公司将实施2023年年度利润分配，每股派发现金红利0.1元（含税），共计派发现金红利15,875,619.50元。股权登记日为2024年6月20日。

本次利润分配方案已于2024年5月20日召开的2023年年度股东大会上审议通过。根据方案，所有持有上海雅仕A股股票的股东均将享有本次现金红利。

截至2023年12月31日，上海雅仕母公司未分配利润为212,659,764.41元。本次利润分配占公司2023年合并报表归属于母公司股东的净利润比例为162.36%。

公司表示，本次利润分配是公司回馈股东、完善公司治理结构的重要举措，有利于增强股东信心，促进公司长期健康发展。

关于上海雅仕

上海雅仕投资发展股份有限公司是一家专业从事房地产开发经营的上市公司，公司主要业务包括住宅、商业、写字楼等房地产开发经营。公司拥有丰富的房地产开发经验和专业的房地产开发团队，在上海和江苏等地开发了多个高品质房地产项目。

新闻来源

• 上海雅仕投资发展股份有限公司公告：https://feeds-drcn.cloud.huawei.com.cn/landingpage/latest?docid=10510281704712&to_app=hwbrowser&dy_scenario=relate&tn=35a41e226d600735c2b5971d8f991901e7bc9c964f8bf05a11646ad0fe4a5da5&channel=-1&ctype=news&cpid=666&r=CN&ifl=zh_CN
• 上海证券交易所公告：https://www.sse.com.cn/disclosure/listedinfo/announcement/c/new/2024-06-14/688798_20240614_6AKO.pdf

免责声明

本文仅供参考，不构成任何投资建议。投资者应自行判断投资决策。